NASDAQ: GALTGalectin Therapeutics Inc Stock
$3.29-0.09 (-2.66%)
Updated Apr 24, 2024
GALT Price
$3.29
Fair Value Price
-$0.77
Market Cap
$203.66M
52 Week Low
$1.28
52 Week High
$4.27
P/E
-4.45x
P/B
-3.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$44.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.43
Operating Cash Flow
-$33M
Beta
1.05
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GALT Overview
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GALT ($3.29) is overvalued by 528.9% relative to our estimate of its Fair Value price of -$0.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GALT ($3.29) is not significantly undervalued (528.9%) relative to our estimate of its Fair Value price of -$0.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GALT due diligence checks available for Premium users.
Be the first to know about important GALT news, forecast changes, insider trades & much more!
GALT News
Valuation
GALT fair value
Fair Value of GALT stock based on Discounted Cash Flow (DCF)
Price
$3.29
Fair Value
-$0.77
Undervalued by
528.90%
GALT ($3.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GALT ($3.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GALT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.45x
Industry
15.69x
Market
41.27x
GALT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.29x
Industry
5.86x
GALT's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.0M
Profit Margin
0%
GALT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$28.2M
Liabilities
$88.4M
Debt to equity
-1.43
GALT's short-term assets ($27.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GALT's long-term liabilities ($72.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GALT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.7M
Investing
$0.0
Financing
$10.0M
GALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GALT vs Biotech Stocks
Galectin Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.